
We are a global biotech company dedicated to pioneering novel therapies for psychiatric and neurological disorders that impact millions of people worldwide.

We are a global biotech company dedicated to pioneering novel therapies for psychiatric and neurological disorders that impact millions of people worldwide.

Our Mission
At NeuShen, central nervous system (CNS) disorders are our exclusive focus. Our mission is to create innovative drug candidates that stand out. Through rigorous R&D and extensive clinical expertise, we strive daily to bring impactful medicines closer to patients.
We are a passionate group of scientists and professionals committed to advancing CNS disorder treatments. We aim to cultivate an environment where we champion the values of excellence, integrity, and collaboration.
year of establishment
novel compounds in development
average years of CNS experience of our founders
proprietary IPs
Our Focus
Depression
Depression, or major depressive disorder, stands as one of the most prevalent mental health conditions worldwide, impacting every facet of a patient's life and imposing significant societal burdens. Despite the existence of various effective antidepressant drugs, the quest for improved treatments remains ongoing. We are making steady progress in this pursuit.
Read More

Schizophrenia
Schizophrenia is a severe mental disorder characterized by recurring episodes of psychosis that require long-term care. Millions of people globally are estimated to be living with this condition, for which there is currently no cure. We are actively developing novel treatments for schizophrenia that are safer and more effective.
Read MoreNeurological Disorders
Neurological disorders comprise a wide range of conditions caused by abnormities in the nervous system that result in diverse symptoms affecting mobility, cognition and other functions. Prominent examples include epilepsy, Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), etc. We recognize immense opportunities in this disease area and aspire to be at the forefront of advancing innovative treatments.
Read More
Current Pipeline
DISEASE AREA
COMPOUND
INDICATION
DISCOVERY
IND ENABLING
PHASE I
PHASE II
PHASE III
Schizophrenia
NS-136
(mAChR4 PAM)
Schizophrenia Psychosis in Alzheimer's disease
Depression
NS-041
(KCNQ2/3 Opener)
Epilepsy
Mood disorders
Pain
NS-015
(Undisclosed)
Treatment-resistant depression
NS-031
(Undisclosed)
Treatment-resistant depression
Neurological Disorders
NS-050
(Undisclosed)
Alzheimer's disease Parkinson’s disease
N-999
(Undisclosed)
Alzheimer's disease Parkinson’s disease
Latest News
